{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:31:30Z","timestamp":1770154290544,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003968","name":"national science foundation of Iran","doi-asserted-by":"crossref","award":["94013422"],"award-info":[{"award-number":["94013422"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00253-016-7422-y","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T02:33:25Z","timestamp":1457577205000},"page":"7051-7060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB\/c mice model"],"prefix":"10.1007","volume":"100","author":[{"given":"Maryam","family":"Heidari-Kharaji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delaram","family":"Doroud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Habibzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"7422_CR1","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/1521-4141(200010)30:10<2935::AID-IMMU2935>3.0.CO;2-Q","volume":"30","author":"J Alexander","year":"2000","unstructured":"Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30:2935\u20132943","journal-title":"Eur J Immunol"},{"key":"7422_CR2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.10.2.298","volume":"10","author":"J Alvar","year":"1997","unstructured":"Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J (1997) Leishmania and human immunodeficiency virus coinfection: the first 10\u00a0years. Clin Microbiol Rev 10:298\u2013319","journal-title":"Clin Microbiol Rev"},{"key":"7422_CR3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","volume":"61","author":"J Alvar","year":"2006","unstructured":"Alvar J, Croft S, Olliaro P (2006) Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 61:223\u2013274","journal-title":"Adv Parasitol"},{"key":"7422_CR4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/infdis\/154.6.1003","volume":"154","author":"R Badaro","year":"1986","unstructured":"Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, Teixeira R, Johnson WD (1986) New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 154:1003\u20131011","journal-title":"J Infect Dis"},{"key":"7422_CR5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1179\/2047773213Y.0000000097","volume":"107","author":"A Badirzadeh","year":"2013","unstructured":"Badirzadeh A, Mohebali M, Ghasemian M, Amini H, Zarei Z, Akhoundi B, Hajjaran H, Emdadi D, Molaei S, Kusha A (2013) Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral leishmaniasis, northwestern Iran 2002\u20132011: a case series. Pathog Glob Health 107:194\u2013197","journal-title":"Pathog Glob Health"},{"key":"7422_CR6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","volume":"368","author":"A Ben Salah","year":"2013","unstructured":"Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S (2013) Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. New Engl J Med 368:524\u2013532","journal-title":"New Engl J Med"},{"key":"7422_CR7","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/00002030-199910010-00015","volume":"13","author":"N Berhe","year":"1999","unstructured":"Berhe N, Wolday D, Hailu A, Abraham Y, Ahmed A, Gebre-Michael T, Desjeux P, Sonnerborg A, Akuffo H, Britton S (1999) HIV viral load and response to antileishmanial chemotherapy in co-infected patients. Aids 13:1921\u20131925","journal-title":"Aids"},{"key":"7422_CR8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4103\/0378-6323.162328","volume":"81","author":"EA Bseiso","year":"2015","unstructured":"Bseiso EA, Nasr M, Sammour O, El Gawad NAA (2015) Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol 81:457","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"7422_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08982100903015025","volume":"20","author":"G Carneiro","year":"2010","unstructured":"Carneiro G, Santos DCM, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LAM (2010) Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 20:16\u201323","journal-title":"J Liposome Res"},{"key":"7422_CR10","doi-asserted-by":"crossref","unstructured":"Chaudhari M, Desai P, Patel P, Patravale V (2015) Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module. Drug Deliv and Transl Res:1\u201311 doi:10.1007\/s13346\u2013015-0267-6","DOI":"10.1007\/s13346-015-0267-6"},{"key":"7422_CR11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","volume":"19","author":"SL Croft","year":"2003","unstructured":"Croft SL, Coombs GH (2003) Leishmaniasis\u2013current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19:502\u2013508","journal-title":"Trends Parasitol"},{"key":"7422_CR12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","volume":"59","author":"AA Date","year":"2007","unstructured":"Date AA, Joshi MD, Patravale VB (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59:505\u2013521","journal-title":"Adv Drug Deliv Rev"},{"key":"7422_CR13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0035-9203(01)90223-8","volume":"95","author":"P Desjeux","year":"2001","unstructured":"Desjeux P (2001) The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95:239\u2013243","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7422_CR14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2011.04.011","volume":"153","author":"D Doroud","year":"2011","unstructured":"Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, Rafati S (2011) Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 153:154\u2013162","journal-title":"J Control Release"},{"key":"7422_CR15","first-page":"80","volume":"2","author":"P Ekambaram","year":"2012","unstructured":"Ekambaram P, Sathali AAH, Priyanka K (2012) Solid lipid nanoparticles: a review. Sci Rev Chem Commun 2:80\u2013102","journal-title":"Sci Rev Chem Commun"},{"key":"7422_CR16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4049\/jimmunol.151.2.907","volume":"151","author":"T Evans","year":"1993","unstructured":"Evans T, Thai L, Granger D, Hibbs J (1993) Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol 151:907\u2013915","journal-title":"J Immunol"},{"key":"7422_CR17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1081\/DDC-120030423","volume":"30","author":"LS Ferreira","year":"2004","unstructured":"Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA (2004) In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 30:289\u2013296","journal-title":"Drug Dev Ind Pharm"},{"key":"7422_CR18","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","volume":"11","author":"MM Gaspar","year":"2015","unstructured":"Gaspar MM, Calado S, Pereira J, Ferronha H, Correia I, Castro H, Tomas AMC, Maria EM (2015) Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems. Nanomed Nanotechnol 11:1851\u20131860","journal-title":"Nanomed Nanotechnol"},{"key":"7422_CR19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2011.12.037","volume":"424","author":"M Ghadiri","year":"2012","unstructured":"Ghadiri M, Fatemi S, Vatanara A, Doroud D, Najafabadi AR, Darabi M, Rahimi AA (2012) Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. Int J Pharm 424:128\u2013137","journal-title":"Int J Pharm"},{"key":"7422_CR20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12257-010-0331-5","volume":"16","author":"M Ghadiri","year":"2011","unstructured":"Ghadiri M, Vatanara A, Doroud D, Najafabadi AR (2011) Paromomycin loaded solid lipid nanoparticles: characterization of production parameters. Biotechnol Bioprocess Eng 16:617\u2013623","journal-title":"Biotechnol Bioprocess Eng"},{"key":"7422_CR21","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01319-08","volume":"53","author":"MR Jaafari","year":"2009","unstructured":"Jaafari MR, Bavarsad N, Bazzaz BSF, Samiei A, Soroush D, Ghorbani S, Heravi MML, Khamesipour A (2009) Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB\/c mice. Antimicrob Agents Chemother 53:2259\u20132265","journal-title":"Antimicrob Agents Chemother"},{"key":"7422_CR22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s12010-014-1084-y","volume":"174","author":"V Jain","year":"2014","unstructured":"Jain V, Gupta A, Pawar VK, Asthana S, Jaiswal AK, Dube A, Chourasia MK (2014) Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol 174:1309\u20131330","journal-title":"Appl Biochem Biotechnol"},{"key":"7422_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejpb.2008.09.003","volume":"71","author":"MD Joshi","year":"2009","unstructured":"Joshi MD, Muller RH (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71:161\u2013172","journal-title":"Eur J Pharm Biopharm"},{"key":"7422_CR24","doi-asserted-by":"crossref","unstructured":"Kalantari H, Hemmati AA, Bavarsad N, Rezaie A, Ahmadi S (2014) Effect of topical nanoliposomes of paromomycin on rats liver and kidney jundishapur. J Natl Pharm 9","DOI":"10.17795\/jjnpp-17565"},{"key":"7422_CR25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/dta.339","volume":"5","author":"W Khan","year":"2013","unstructured":"Khan W, Sharma SS, Kumar N (2013) Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres. Drug Test Anal 5:453\u2013460","journal-title":"Drug Test Anal"},{"key":"7422_CR26","doi-asserted-by":"crossref","unstructured":"Kharaji MH, Doroud D, Taheri T, Rafati S (2015) Drug targeting to macrophages with solid lipid nanoparticles harboring paromomycin: an in vitro evaluation against L. major and L. tropica AAPS. PharmSciTech:1\u201310","DOI":"10.1208\/s12249-015-0439-1"},{"key":"7422_CR27","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1371\/journal.pntd.0000381","volume":"3","author":"DH Kim","year":"2009","unstructured":"Kim DH, Chung HJ, Bleys J, Ghohestani RF (2009) Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 3:e381","journal-title":"PLoS Negl Trop Dis"},{"key":"7422_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jim.2008.01.004","volume":"333","author":"D Kram","year":"2008","unstructured":"Kram D, Th\u00e4le C, Kolodziej H, Kiderlen AF (2008) Intracellular parasite kill: flow cytometry and NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation. J Immunol Methods 333:79\u201388","journal-title":"J Immunol Methods"},{"key":"7422_CR29","first-page":"62","volume":"5","author":"R Lopez-Garcia","year":"2015","unstructured":"Lopez-Garcia R, Ganem-Rondero A (2015) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): occlusive effect and penetration enhancement ability. J Cosmet Dermatol Sci Appl 5:62","journal-title":"J Cosmet Dermatol Sci Appl"},{"key":"7422_CR30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1358\/mf.2005.27.2.876286","volume":"27","author":"K Manjunath","year":"2005","unstructured":"Manjunath K, Reddy J, Venkateswarlu V (2005) Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27:127\u2013144","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"7422_CR31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4269\/ajtmh.14-0040a","volume":"90","author":"B Monge-Maillo","year":"2014","unstructured":"Monge-Maillo B, Lopez-Velez R (2014) Topical paromomycin and gentamicin for new world cutaneous leishmaniasis in Panama. AmJTrop Med Hyg 90:1191\u20131191","journal-title":"AmJTrop Med Hyg"},{"key":"7422_CR32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/EC.00196-09","volume":"9","author":"MA Morales","year":"2010","unstructured":"Morales MA, Pescher P, Sp\u00e4th GF (2010) Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage. Eukaryot Cell 9:22\u201330","journal-title":"Eukaryot Cell"},{"key":"7422_CR33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1023\/A:1012043315093","volume":"14","author":"RH Muller","year":"1997","unstructured":"Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W (1997) Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 14:458\u2013462","journal-title":"Pharm Res"},{"key":"7422_CR34","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1128\/AAC.47.8.2513-2517.2003","volume":"47","author":"HW Murray","year":"2003","unstructured":"Murray HW, Brooks EB, DeVecchio JL, Heinzel FP (2003) Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother 47:2513\u20132517","journal-title":"Antimicrob Agents Chemother"},{"key":"7422_CR35","first-page":"51","volume":"14","author":"JM Mutiso","year":"2013","unstructured":"Mutiso JM, Macharia JC, Gicheru MM, Ozwara H, Moodi B, Aliabadian M, Moshaverinia A, Kakhki OM, Chaudhary A, Verma C (2013) Immunology of leishmaniasis. Sci Parasitol 14:51\u201361","journal-title":"Sci Parasitol"},{"key":"7422_CR36","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1128\/AAC.00628-13","volume":"57","author":"WR Ravis","year":"2013","unstructured":"Ravis WR, Llanos-Cuentas A, Sosa N, Kreishman-Deitrick M, Kopydlowski KM, Nielsen C, Smith KS, Smith PL, Ransom JH, Lin YJ (2013) Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. Antimicrob Agents Chemother 57:4809\u20134815","journal-title":"Antimicrob Agents Chemother"},{"key":"7422_CR37","doi-asserted-by":"crossref","unstructured":"Rodrigues IA, Mazotto AM, Cardoso V, Alves RL, Amaral ACF, Silva JRA, Pinheiro AS, Vermelho AB (2015) Natural products: insights into leishmaniasis inflammatory response. Mediat Inflamm 2015","DOI":"10.1155\/2015\/835910"},{"key":"7422_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","volume":"30","author":"C Schwarz","year":"1994","unstructured":"Schwarz C, Mehnert W, Lucks J, M\u00fcller R (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery. I. production, characterization and sterilization. J Control Release 30:83\u201396","journal-title":"J Control Release"},{"key":"7422_CR39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/0975-8453.59509","volume":"1","author":"P Shah","year":"2010","unstructured":"Shah P, Bhalodia D, Shelat P (2010) Nanoemulsion: a pharmaceutical review. System Rev Pharm 1:24","journal-title":"System Rev Pharm"},{"key":"7422_CR40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","volume":"5","author":"N Singh","year":"2012","unstructured":"Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pacific J Trop Med 5:485\u2013497","journal-title":"Asian Pacific J Trop Med"},{"key":"7422_CR41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","volume":"38","author":"S Sundar","year":"2004","unstructured":"Sundar S, Mehta H, Suresh A, Singh SP, Madhukar R, Murray HW (2004) Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38:377\u2013383","journal-title":"Clin Infect Dis"},{"key":"7422_CR42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.exppara.2015.01.008","volume":"150","author":"T Taheri","year":"2015","unstructured":"Taheri T, Nik HS, Seyed N, Doustdari F, Etemadzadeh M-H, Torkashvand F, Rafati S (2015) Generation of stable L. major\u00a0+\u00a0EGFP-LUC and simultaneous comparison between EGFP and luciferase sensitivity. Exp Parasitol 150:44\u201355","journal-title":"Exp Parasitol"},{"key":"7422_CR43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijpharm.2006.12.043","volume":"337","author":"W Tiyaboonchai","year":"2007","unstructured":"Tiyaboonchai W, Tungpradit W, Plianbangchang P (2007) Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 337:299\u2013306","journal-title":"Int J Pharm"},{"key":"7422_CR44","doi-asserted-by":"crossref","unstructured":"Trufant JW, Lewin JM, Hale CS, Meehan SA, Pomeranz MK (2015) New world cutaneous leishmaniasis. Dermatol Online J 20","DOI":"10.5070\/D32012025051"},{"key":"7422_CR45","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1016\/j.msec.2013.07.047","volume":"33","author":"P Wang","year":"2013","unstructured":"Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z (2013) The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C 33:4802\u20134808","journal-title":"Mater Sci Eng C"},{"key":"7422_CR46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.micpath.2004.11.002","volume":"38","author":"ME Wilson","year":"2005","unstructured":"Wilson ME, Jeronimo SM, Pearson RD (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38:147\u2013160","journal-title":"Microb Pathog"},{"key":"7422_CR47","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.biomaterials.2004.07.050","volume":"26","author":"KY Win","year":"2005","unstructured":"Win KY, Feng S-S (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomater 26:2713\u20132722","journal-title":"Biomater"},{"key":"7422_CR48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4172\/1948-5948.1000250","volume":"7","author":"M Zandieh","year":"2015","unstructured":"Zandieh M, Kashi T, Taheri T, Zahedifard F, Taslimi Y (2015) Assessment of protection induced by DNA and live vaccine encoding leishmania MHC class I restricted epitopes against L. major challenge in balb\/c mice model. J Microb Biochem Technol 7:427\u2013438","journal-title":"J Microb Biochem Technol"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-016-7422-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00253-016-7422-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-016-7422-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T05:25:50Z","timestamp":1692249950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00253-016-7422-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":48,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["7422"],"URL":"https:\/\/doi.org\/10.1007\/s00253-016-7422-y","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}